세계의 비뇨생식기 치료제 시장 보고서(2025년)
Genitourinary Drugs Global Market Report 2025
상품코드 : 1764327
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비뇨생식기 치료제 시장 규모는 향후 수년간 안정된 성장이 예상되며 2029년까지 CAGR 2.9%로 347억 6,000만 달러로 성장할 전망입니다. 예상되는 성장의 원동력은 요로 감염 환자의 지속적인 증가, 성 건강에 대한 의식 증가, 헬스케어 인프라 개선, 호르몬 보충 요법 수요 증가, 경구 피임약 채용 확대 등이 있습니다. 이 기간에 예상되는 주요 동향은 제형 및 전달 기술의 혁신, 디지털 건강 플랫폼의 이용, 기술을 활용한 맞춤형 치료 접근법, 생물학적 요법의 출현, 정밀 의료 기술의 발전 등이 있습니다.

비뇨생식기 질환의 유병률 증가는 비뇨생식기 치료제 시장의 성장을 가속할 것으로 예측됩니다. 이 질병은 비뇨기와 생식기를 포함한 비뇨생식기 시스템에 영향을 미치며 감염, 암, 구조적 또는 기능적 문제와 같은 다양한 상태를 포함합니다. 이러한 질병의 발생률 증가는 노화와 관련된 변화가 비뇨기 및 생식기계의 건강 문제의 발생 위험을 증가시키기 때문에 주로 노령 인구에서 발생합니다. 비뇨생식기 치료제는 감염, 염증 및 기능 장애에 대처함으로써 이러한 질병의 관리에 중요한 역할을 수행하고, 궁극적으로는 삶의 질을 높이는 표적 중심적 치료를 통해 환자의 결과를 개선합니다. 예를 들어, 2024년 4월 미국암협회의 보고에 따르면 2022년에는 세계 약 2,000만명이 새롭게 암으로 진단되었으며 970만명이 사망하였고, 2050년에는 3,500만명으로 증가할 것으로 예측되고 있습니다. 그 결과, 비뇨생식기 질환의 유병률 증가가 비뇨생식기 치료제 시장의 확대에 기여하고 있습니다.

비뇨생식기 치료제 시장 진출 기업은 치료의 편의성을 향상시켜 환자의 순응도를 높이고 감염증과 효과적으로 싸우기 위해 경구 항생제 등의 혁신적인 치료법의 개발을 우선하고 있습니다. 2025년 3월, GSK plc는 12세 이상의 여성용으로 합병증 없는 요로 감염 치료제로 Blujepa(게포티다신)의 FDA 승인을 받았습니다. 해당 치료제는 2개의 필수 효소를 표적으로 하여 세균의 DNA 복제를 저해함으로써 기능합니다. 이러한 독특한 결합 부위는 항생제 내성을 극복하는데 도움이 되며 종래의 항생제에 비해 안전성과 효능이 향상된 보다 표적 중심적인 치료를 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 팬데믹과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Genitourinary drugs are pharmaceutical agents used to treat conditions that impact the urinary and reproductive systems, including the kidneys, bladder, urethra, and genital organs. Their primary function is to address infections, manage overactive bladder, treat erectile dysfunction, alleviate urinary discomfort, and regulate hormonal activity. These medications aim to restore normal genitourinary functions and enhance patients' overall quality of life.

The key categories of genitourinary drugs include urologicals, hormonal therapies, gynecological treatments, anti-infectives, and other related products. Urologicals are a class of drugs specifically designed to manage disorders affecting the urinary system and male reproductive organs. These medications can be administered via oral, parenteral, or topical routes and are used to treat various conditions such as urinary tract infections (UTIs), benign prostatic hyperplasia (BPH), prostate cancer, overactive bladder, bladder cancer, and more. Distribution channels for these drugs include hospital pharmacies, retail and drugstore pharmacies, as well as online pharmacies.

The genitourinary drugs market research report is one of a series of new reports from The Business Research Company that provides genitourinary drugs market statistics, including the genitourinary drugs industry global market size, regional shares, competitors with the genitourinary drugs market share, detailed genitourinary drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the genitourinary drugs industry. This genitourinary drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The genitourinary drugs market size has grown steadily in recent years. It will grow from $30.07 billion in 2024 to $31.02 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. This historical growth can be attributed to the rising incidence of urinary tract infections, a growing number of benign prostatic hyperplasia cases, increasing public awareness regarding sexual health, an aging global population, and a higher prevalence of chronic kidney diseases.

The genitourinary drugs market size is expected to see steady growth in the next few years. It will grow to $34.76 billion in 2029 at a compound annual growth rate (CAGR) of 2.9%. Forecasted growth will be driven by a continued rise in urinary tract infection cases, increasing awareness about sexual wellness, improvement in healthcare infrastructure, higher demand for hormone replacement therapies, and greater adoption of oral contraceptives. Key trends anticipated during this period include innovations in drug formulation and delivery technologies, the use of digital health platforms, personalized treatment approaches powered by technology, the emergence of biologic therapies, and progress in precision medicine techniques.

The increasing prevalence of genitourinary disorders is anticipated to drive the growth of the genitourinary drugs market. These disorders impact the genitourinary system, which includes the urinary and reproductive organs, and encompass a range of conditions such as infections, cancers, and structural or functional issues. The rising incidence of these conditions is largely attributed to the aging population, as age-related changes elevate the risk of developing urinary and reproductive health problems. Genitourinary drugs play a critical role in managing these disorders by addressing infections, inflammation, and dysfunction, ultimately improving patient outcomes through targeted, convenient treatments that enhance quality of life. For example, according to a report by the American Cancer Society in April 2024, approximately 20 million new cancer cases were diagnosed worldwide in 2022, resulting in 9.7 million deaths, with projections estimating a rise to 35 million cases by 2050. Consequently, the increasing prevalence of genitourinary disorders is contributing to the expansion of the genitourinary drugs market.

Companies operating in the genitourinary drugs market are prioritizing the development of innovative treatments such as oral antibiotics to improve therapeutic convenience, enhance patient adherence, and effectively combat infections. Oral antibiotics are medications administered by mouth to treat bacterial infections. In March 2025, GSK plc, a pharmaceutical company based in the UK, secured FDA approval for Blujepa (gepotidacin) to treat uncomplicated urinary tract infections in women and girls aged 12 years and older. This novel, first-in-class oral antibiotic functions by inhibiting bacterial DNA replication through the targeting of two essential enzymes-DNA gyrase and topoisomerase IV. Its unique binding sites help overcome antibiotic resistance, offering a more targeted treatment with improved safety and efficacy compared to traditional antibiotics.

In December 2023, Pfizer Inc., a U.S.-based pharmaceutical company, completed the acquisition of Seagen Inc. for $43 billion. This acquisition is intended to enhance Pfizer's cancer drug portfolio by integrating Seagen's advanced antibody-drug conjugate (ADC) technology with Pfizer's global capabilities and expertise. Seagen Inc., a biotechnology company based in the U.S., is recognized for its innovative genitourinary cancer therapies, including Padcev, which is used in the treatment of advanced bladder cancer.

Major players in the genitourinary drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Ipsen Societe Anonyme, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals Public Limited Company, Zydus Lifesciences Limited, Endo International Public Limited Company, Takeda Pharmaceutical Company Limited, Zydus Lifesciences Limited, Melinta Therapeutics Inc., and Asieris Pharmaceuticals.

North America was the largest region in the genitourinary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in genitourinary drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the genitourinary drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The genitourinary drugs market consists of sales of urinary acidifiers and alkalinizers, desmopressin, diuretics, urinary antispasmodics, anti-infectives, and hormone replacement therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Genitourinary Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on genitourinary drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for genitourinary drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genitourinary drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Genitourinary Drugs Market Characteristics

3. Genitourinary Drugs Market Trends And Strategies

4. Genitourinary Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Genitourinary Drugs Growth Analysis And Strategic Analysis Framework

6. Genitourinary Drugs Market Segmentation

7. Genitourinary Drugs Market Regional And Country Analysis

8. Asia-Pacific Genitourinary Drugs Market

9. China Genitourinary Drugs Market

10. India Genitourinary Drugs Market

11. Japan Genitourinary Drugs Market

12. Australia Genitourinary Drugs Market

13. Indonesia Genitourinary Drugs Market

14. South Korea Genitourinary Drugs Market

15. Western Europe Genitourinary Drugs Market

16. UK Genitourinary Drugs Market

17. Germany Genitourinary Drugs Market

18. France Genitourinary Drugs Market

19. Italy Genitourinary Drugs Market

20. Spain Genitourinary Drugs Market

21. Eastern Europe Genitourinary Drugs Market

22. Russia Genitourinary Drugs Market

23. North America Genitourinary Drugs Market

24. USA Genitourinary Drugs Market

25. Canada Genitourinary Drugs Market

26. South America Genitourinary Drugs Market

27. Brazil Genitourinary Drugs Market

28. Middle East Genitourinary Drugs Market

29. Africa Genitourinary Drugs Market

30. Genitourinary Drugs Market Competitive Landscape And Company Profiles

31. Genitourinary Drugs Market Other Major And Innovative Companies

32. Global Genitourinary Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Genitourinary Drugs Market

34. Recent Developments In The Genitourinary Drugs Market

35. Genitourinary Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기